OHSU researchers developed SU212, a new molecule disabling the ENO1 enzyme. It significantly reduces triple-negative breast cancer growth and spread in mouse models, offering a promising therapy for this aggressive cancer and potentially other cancer types.
CRISPR technology reverses chemotherapy resistance in lung cancer by disabling the NRF2 gene. This improves drug sensitivity and slows tumor growth, offering a novel strategy for resistant cancers.
Immunotherapy efficacy can be boosted by preserving lymph nodes, crucial for T cell training. Research suggests lymph node removal during surgery may hinder cancer treatment response. Gut bacteria also influence immunotherapy.
Blocking macropinocytosis, a nutrient-scavenging process used by pancreatic cancer (PDAC) cells, reshapes the tumor microenvironment, enhancing immunotherapy and radiation effectiveness. This improves drug delivery and immune cell access.
Researchers developed a metal-free, blue light method using modified carbohydrates (thiosugars) to combat antibiotic-resistant infections, cancer, and gram-negative pathogens like Pseudomonas aeruginosa. This advance enhances drug delivery and reduces toxicity.
